DAY 1 - Saturday, April 26
Welcome
Ophthalmology Times welcomes ophthalmic professionals from around the world to Boston. Our four-day coverage of this year’s meeting of the American Society of Cataract and Refractive Surgery begins today and includes the latest research findings and clinical news of interest to readers.
Enjoy the meeting!
|
|
GOVERNMENT RELATIONS
Sen. Rand Paul slams ICD-10, 'Obamacare'
Nothing was off limits as Sen. Rand Paul, MD (R-KY) put the Affordable Care Act (ACA), the International Classification of Diseases (ICD)-10, and the U.S. government on blast for creating a gigantic headache for American patients and physicians alike. » MORE
|
|
GLAUCOMA DAY
How glaucoma specialty continues to evolve
Glaucoma is now in a post-Renaissance period with far superior medications, better lasers, and the potential for individualized treatments for patients, according to Thomas W. Samuelson, MD. » MORE
|
|
Using health policy to advocate for patients
Glaucoma specialists can be advocates for their patients on a number of levels. On a daily basis, ophthalmologists help overcome barriers to treatment and offer solutions to patients for instilling medications, involving family members in their care, organizing services for patients, and providing educational materials, said Cynthia Mattox, MD. » MORE
|
|
Cataract surgery: Identifying dysphotopsia
Following cataract surgery, patients can present with a variety of visual complaints—i.e., dysphotopsias, aberrant optical phenomena that interfere with vision after IOL implantation. Positive dysphotopsias include rainbows, streaks, crescents, rings, halos, and veiling glare, haze, and fog. Negative dysphotopsias are relative and absolute scotomas, said Jack T. Holladay, MD. » MORE
|
|
FROM THE SHOW FLOOR
Genetic test designed to make LASIK safer
Avellino Lab USA announced the availability of its new Avellino DNA dual test for LASIK safety, a genetic test that can detect both Avellino Corneal Dystrophy (ACD) and another genetic mutation, Granular Corneal Dystrophy type 1 (GCD1). » MORE
|
DISCLAIMER:
This information has been independently developed and provided by the editors of Ophthalmology Times. The sponsor does not endorse and is not responsible for the accuracy of the content or for practices or standards of non-sponsor sources.
| |
|
 Top Tweets
|
|
We welcome your feedback!
Please send your comments to:
Mark L. Dlugoss
Group Content Director
Advanstar Eye Health Group
mdlugoss@advanstar.com |
|
|
